Uncertainties in endocrine substitution therapy for central endocrine insufficiencies: Growth hormone deficiency

Handbook of Clinical Neurology

Volumn 124, Issue , 2014, Pages 407-416

  Erfurth, Eva Marie ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Bone mineral density; Cardiovascular risk; Cranial radiotherapy; GH deficiency; GH deficiency phenotypes; GH therapy; Hypothalamic damage; Isolated GH deficiency; Multiple hormone deficiency

Indexed keywords

HUMAN GROWTH HORMONE;

ADVERSE EFFECTS; ANIMAL; BLOOD; BONE DENSITY; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DEFICIENCY; DRUG EFFECTS; ENDOCRINE SYSTEM DISEASES; HORMONE SUBSTITUTION; HUMAN; HYPOTHALAMUS; METABOLISM; PHYSIOLOGY; PROCEDURES;

ANIMALS; BONE DENSITY; CARDIOVASCULAR DISEASES; ENDOCRINE SYSTEM DISEASES; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOTHALAMUS;

EID: 84907481983     PISSN: 00729752     EISSN: 22124152     Source Type: Book Series    
DOI: 10.1016/B978-0-444-59602-4.00028-9     Document Type: Chapter

References (76)

1. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004, 291:1701-1712.
2. Barrett-Connor E. Clinical review 162: Cardiovascular Endocrinology 3. An epidemiologist looks at hormones and heart disease in women. J Clin Endocrinol Metab 2003, 88:4031-4042.
3. Bowers D.C., Liu Y., Leisenring W., et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2006, 24:5277-5282.
4. Bray G.A., Gallagher T.F. Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a review of the literature. Medicine (Baltimore) 1975, 54:301-330.
5. Bray G.A., Inoue S., Nishizawa Y. Hypothalamic obesity. The autonomic hypothesis and the lateral hypothalamus. Diabetologia 1981, 20(Suppl):366-377.
6. Brennan B.M.D., Rahim A., Mackie E.M., et al. Growth hormone status in adults treated for acute lymphoblastic leukaemia in childhood. Clin Endocrinol (Oxf) 1998, 48:777-783.
7. Brennan B.M., Rahim A., Blum W.F., et al. Hyperleptinaemia in young adults following cranial irradiation in childhood: growth hormone deficiency or leptin insensitivity?. Clin Endocrinol (Oxf) 1999, 50:163-169.
8. Bülow B., Erfurth E.M. A low individualized GH dose in young patients with childhood onset GH deficiency normalized serum IGF-I without significant deterioration in glucose tolerance. Clin Endocrinol (Oxf) 1999, 50:45-55.
9. Bülow B., Hagmar L., Mikoczy Z., et al. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997, 46:75-81.
10. Bülow B., Attewell R., Hagmar L., et al. Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence. J Clin Endocrinol Metab 1998, 83:3897-3904.
11. Bülow B., Link K., Ahrén B., et al. Survivors of childhood acute lymphoblastic leukaemia, with radiation-induced GH deficiency, exhibit hyperleptinaemia and impaired insulin sensitivity, unaffected by 12 months of GH treatment. Clin Endocrinol (Oxf) 2004, 61:683-691.
12. Carroll P.V., Christ E.R. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab 1998, 3:382-395.
13. Cornier M.A., Dabalea A., Hernandez T.L., et al. The metabolic syndrome. Endocr Rev 2008, 29:777-822.
14. Crowley R.K., Hamnvik O.P., O'Sullivan E.P., et al. Morbidity and mortality in patients with craniopharyngioma after surgery. Clin Endocrinol (Oxf) 2010, 73:516-521.
15. Cuneo R.C., Salomon F., McGauley G.A., et al. The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf) 1992, 37:387-397.
16. De Boer H., Blok G.J., van Lingen A., et al. The consequences of childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res 1994, 9:1319-1326.
17. Degerblad M., Bengtsson B.Å., Bramnert M., et al. Reduced bone mineral density in adults with growth hormone (GH) deficiency: increased bone turnover during 12 months of GH substitution therapy. Eur J Endocrinol 1995, 133:180-188.
18. Do Prado W.L., de Piano A., Lazaretti-Castro M., et al. Relationship between bone mineral density, leptin and insulin concentration in Brazilian obese adolscents. J Bone Miner Metab 2009, 27:613-619.
19. Duff J., Meyer F.B., Ilstrup D.M., et al. Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery 2000, 46:291-302.
20. Erfurth E.M., Bülow B., Svahn-Tapper G., et al. Riskfactors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors. J Clin Endocrinol Metab 2002, 87:4892-4899.
21. Felson D.T., Zhang Y., Hannan M.T., et al. Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res 1993, 8:567-573.
22. Fernholm R., Bramnert M., Hägg E., et al. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. J Clin Endocrinol Metab 2000, 85:4104-4112.
23. Follin C., Thilén U., Österberg K., et al. Cardiovascular risk, cardiac function, physical activity and quality of life with and without long-term GH therapy in adult survivors of childhood acute lymphoblastic leukaemia. J Clin Endocrinol Metab 2010, 95:3726-3735.
24. Follin C., Link K., Wiebe T., et al. Bone loss after childhood acute lymphoblastic leukaemia: an observational study with and without GH therapy. Eur J Endocrinol 2011, 164:695-703.
25. Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005, 28:1769-1778.
26. Gaillard R.C., Mattsson A.F., Akerblad A.C., et al. Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur J Endocrinol 2012, 166:1069-1077.
27. Gibney J., Wolthers T., Johannsson G., et al. Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men. Am J Physiol Endocrinol Metab 2005, 2:266-271.
28. Gilsanz V., Carlsson M., Roe T., et al. Osteoporosis after cranial irradiation for acute lymphoblastic leukemia. J Pediatr 1990, 117:238-244.
29. Guo Y., Zhao L.J., Shen H., et al. Genetic and environmental correlations between age at menarche and bone mineral density at different skeletal sites. Calcif Tissue Int 2005, 77:356-360.
30. Hamrick M.W., Ferrari S.L. Leptin and the sympathetic connection of fat to bone. Review. Osteoporos Int 2008, 19:905-912.
31. Hetelekidis S., Barnes P.D., Tao M.L., et al. 20-year experience in childhood craniopharyngioma. Int J Radiat Oncol Biol Phys 1993, 27:189-195.
32. Holmer H., Svensson J., Rylander L., et al. Non-fatal stroke, cardiac disease, and diabetes mellitus in hypopituitary patients on complete hormone replacement including GH. J Clin Endocrinol Metab 2007, 92:3560-3567.
33. Holmer H., Svensson J., Rylander L., et al. Fracture incidence in GH deficient patients on complete hormone replacement including GH. J Bone Miner Res 2007, 22:1842-1850.
34. Holmer H., Ekman B., Björk J., et al. Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy. Eur J Endocrinol 2009, 161:671-679.
35. Holmer H., Pozarek G., Wirfält E., et al. Reduced energy expenditure and impaired feeding-related signals but not high energy intake reinforces hypothalamic obesity in adults with childhood onset craniopharyngioma. J Clin Endocrinol Metab 2010, 95:5395-5402.
36. Holmer H., Popovic V., Ekman B., et al. Hypothalamic involvement and insufficient sex steroid supplementation are associated with low bone mineral density in women with childhood onset craniopharyngioma. Eur J Endocrinol 2011, 165:25-31. April.
37. Holmes S.J., Economou G., Whitehouse R.W., et al. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994, 78:669-674.
38. Jarfelt M., Fors H., Lannering B., et al. Bone mineral density and bone turnover in young adult survivors of childhood acute lymphoblastic leukaemia. Eur J Endocrinol 2006, 154:303-309.
39. Karavitaki N., Cudlip S., Adams C.B., et al. Craniopharyngiomas. Endocr Rev 2006, 27:371-397.
40. Kaufman J.M., Taelman P., Vermeulen A., et al. Bone mineral status growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab 1992, 74:118-123.
41. Kreier F., Fliers E., Voshol P.J., et al. Selective parasympathetic innervation of subcutaneous and intra-abdominal fat - functional implications. J Clin Invest 2002, 110:1243-1250.
42. Link K., Moëll C., Garwicz S., et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukaemia in childhood. J Clin Endocrinol Metab 2004, 89:5005-5012.
43. Lustig R.H. Hypothalamic obesity: the sixth cranial. Endocrinopathy Endocrinologist 2002, 12:210-217.
44. Maculty V.M. Insulin-like growth factors and cancer. Br J Cancer 1992, 65:311-320.
45. Mah P.M., Webster J., Jönsson P., et al. Estrogen replacement in women of fertile years with hypopituitarism. J Clin Endocrinol Metab 2005, 90:5964-5969.
46. Mandel K., Atkinson S., Barr R., et al. Skeletal morbidity in childhood acute lymphoblastic leukaemia. J Clin Oncol 2004, 22:2015-2021.
47. Maison P., Griffin S., Nicoue-Beglah M., et al. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 2004, 89:2192-2199.
48. Mayer E.I., Reuter M., Dopfer R.E., et al. Energy expenditure, energy intake and prevalence of obesity after therapy for acute lymphoblastic leukemia during childhood. Horm Res 2000, 53:193-199.
49. Mertens A.C., Liu Q., Neglia J.P., et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2008, 100:1368-1379.
50. Nussey S., Hyer S., Brada M., et al. Bone mineralization after treatment of growth hormone deficiency in survivors of childhood malignancy. Acta Paediatr Suppl 1994, 399:9-14.
51. Oeffinger K.C., Mertens A.C., Sklar C.A., et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2003, 21:1359-1365.
52. Oeffinger K.C., Eshelman D.A., Tomlinson G.E., et al. Providing primary care for long-term survivors of childhood acute lymphoblastic leukemia. J Fam Pract 2000, 49:1133-1146.
53. O'Halloran D., Tsatosoulis A., Whitehouse R., et al. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. J Clin Endocrinol Metab 1993, 76:1344-1348.
54. Ohlsson C., Bengtsson B.Å., Isaksson O.G., et al. Growth hormone and bone. Endocr Rev 1998, 19:55-79.
55. Pereira A.M., Schmid E.M., Schutte P.J., et al. High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma. Clin Endocrinol (Oxf) 2005, 62:197-204.
56. Robson H., Anderson E., Eden O., et al. Chemotherapeutic agents used in the treatment of childhood malignancies have a direct effects on growth plate chondrocyte proliferation. J Endocrinol 1998, 157:225-235.
57. Rivera-Woll L.M., Papalia M., Davis S.R., et al. Androgen insufficiency in women: diagnostic and therapeutic implications. Hum Reprod Update 2004, 10:421-432.
58. Rosén T., Bengtsson B.Å. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990, 336:285-288.
59. Rosén T., Hansson T., Granhed H., et al. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 1993, 129:201-206.
60. Rosén T., Wilhelmsen L., Landin-Whilhelmsen K., et al. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 1997, 137:240-245.
61. Roth C., Wilken B., Hanefels F., et al. Hyperphagia in children with craniopharyngioma is associated with hyperleptinaemia and a failure in the downregulation of appetite. Eur J Endocrinol 1998, 138:89-91.
62. Sala A., Barr R. Osteopenia and cancer in children and adolescents. Cancer 2007, 109:1420-1431.
63. Segerlantz M., Bramnert M., Manhem P., et al. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults. Eur J Endocrinol 2003, 149:511-519.
64. Shaikh M.G., Grundy R.G., Kirk J.M. Reductions in basal metabolic rate and physical activity contribute to hypothalamic obesity. J Clin Endocrinol Metab 2008, 93:2588-2593.
65. Stripp D.C., Maity A., Janss A.J., et al. Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults. Int J Radiat Oncol Biol Phys 2004, 58:714-720.
66. Svensson J., Fowelin J., Landin K., et al. Effects of seven years of growth hormone (GH) replacement therapy on insulin sensitivity in GH deficient adults. J Clin Endocrinol Metab 2002, 87:2121-2127.
67. Talvensaari K.K., Lanning M., Tapanainen P., et al. Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab 1996, 81:3051-3055.
68. Tomlinson J.W., Holden N., Hills R.K., et al. Association between premature mortality and hypopituitarism. Lancet 2001, 357:425-431.
69. Toogood A., Adams J., O'Neill P., et al. Elderly patients with adult-onset growth hormone deficiency are not osteopenic. J Clin Endocrinol Metab 1997, 82:1462-1466.
70. Trivin C., Busiah K., Mahlaoui N., et al. Childhood craniopharyngioma: greater hypothalamic involvement before surgery is associated with higher homeostasis model insulin resistance index. BMC Pediatr 2009, 9:24.
71. van Bunderen C.C., van Nieuwpoort I.C., Arwert L.I., et al. Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. J Clin Endocrinol Metab 2011, 96:3151-3159.
72. Verhelst J., Kendall-Taylor P., Erfurth E.M., et al. Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database). J Clin Endocrinol Metab 2005, 90:4636-4643.
73. Wüster C., Slenczka E., Ziegler R. Increased prevalence of osteoporosis and arteriosclerosis in conventionally substituted anterior pituitary insufficiency: is there a need for additional growth hormone substitution? [In German]. Klin Wochenschr 1991, 69:769-773.
74. Wüster C., Abs R., Bengtsson B.Å., et al. The influence of growth hormone deficiency, growth hormone replacement therapy and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 2001, 2:398-405.
75. Yuen K., Frystyk J., White D., et al. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin Endocrinol (Oxf) 2005, 63:428-436.
76. Zhang Y., Proenca R., Maffei M., et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 1:372.